← Leaderboards
Paul M. Dunman
University Of Nebraska Medical Center
$8,039,441
Attributed
$9,858,122
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $984.1K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,858,122 · 7
By mechanism
R01$8,340,670 · 4
T32$1,067,874 · 1
R21$437,878 · 1
R13$11,700 · 1
Top collaborators
- Daniel Patrick Flaherty5 shared
- Brian M Ward4 shared
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionPathogenOrganismLibrariesSmall MoleculeSeveritiesAntimicrobialBaseStaphylococcus AureusMemberScreeningAntibioticsCellsHigh Throughput ScreeningMediatingHealthcareResponseMrna Transcript DegradationProteinsLaboratoriesDesignEnzymesMolecularBacterial Infections
Grant awards (22)
Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii$708,130
R01 · FY2025 · AI · contact PI
Infection and Immunity: The Pathogenesis of Host-Microbe Interactions$266,460
T32 · FY2025 · AI · contact PI
Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii$708,130
R01 · FY2024 · AI · contact PI
Infection and Immunity: The Pathogenesis of Host-Microbe Interactions$268,680
T32 · FY2024 · AI · contact PI
Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii$715,350
R01 · FY2023 · AI · contact PI
Infection and Immunity: The Pathogenesis of Host-Microbe Interactions$268,773
T32 · FY2023 · AI · contact PI
Antibacterial inhibitors of RnpA$693,668
R01 · FY2022 · AI · contact PI
Infection and Immunity: The Pathogenesis of Host-Microbe Interactions$263,961
T32 · FY2022 · AI · contact PI
Antibacterial inhibitors of RnpA$734,704
R01 · FY2021 · AI · contact PI
Antibacterial inhibitors of RnpA$704,674
R01 · FY2020 · AI · contact PI
Antibacterial inhibitors of RnpA$718,534
R01 · FY2019 · AI · contact PI
Antibacterial inhibitors of RnpA$707,917
R01 · FY2018 · AI · contact PI
Ribonuclease E a novel new Gram-negative antimicrobial target$231,630
R21 · FY2017 · AI · contact PI
Ribonuclease E a novel new Gram-negative antimicrobial target$206,248
R21 · FY2016 · AI · contact PI
Development of AK-based assays for antimicrobial screening$386,610
R01 · FY2015 · AI · contact PI
Development of AK-based assays for antimicrobial screening$386,610
R01 · FY2014 · AI · contact PI
Development of AK-based assays for antimicrobial screening$375,986
R01 · FY2013 · AI · contact PI
Staphylococcus aureus RNA turnover properties$378,563
R01 · FY2011 · AI · contact PI
Staphylococcus aureus RNA turnover properties$379,294
R01 · FY2010 · AI · contact PI
2010 International Conference on Gram-Positive Pathogens.$11,700
R13 · FY2010 · AI · contact PI
Staphylococcus aureus RNA turnover properties$371,250
R01 · FY2009 · AI · contact PI
Staphylococcus aureus RNA turnover properties$371,250
R01 · FY2008 · AI · contact PI